These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 23906938

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [Abstract] [Full Text] [Related]

  • 28. Timing of mTORI usage and outcomes in kidney transplant recipients.
    Lim LM, Kung LF, Kuo MC, Huang AM, Kuo HT.
    Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J, Couchonnal E, Lacaille F, Rivet C, Debray D, Boillot O, Lachaux A, Ackermann O, Gonzales E, Wildhaber BE, Jacquemin E, McLin V.
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
    [Abstract] [Full Text] [Related]

  • 31. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A, Wilde B, Wang J, Tebbe B, Jing L, Wang X, Jian F, Zhu J, Dolff S, Kribben A, Hoyer PF, Witzke O.
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [Abstract] [Full Text] [Related]

  • 32. Renal tubular acidosis in renal transplant patients: the effect of immunosuppressive drugs.
    Tanrisev M, Gungor O, Kocyigit I, Kurtulmus Y, Tugmen C, Colak H, Altunoren O, Kebapci E, Karaca C.
    Ann Transplant; 2015 Feb 09; 20():85-91. PubMed ID: 25659354
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G, Soy-Muner D, Anglada-Martínez H, Riu-Viladoms G, Estefanell-Tejero A, Ribas-Sala J.
    Nefrologia; 2013 Feb 09; 33(3):297-300. PubMed ID: 23712219
    [Abstract] [Full Text] [Related]

  • 38. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T, Segovia R, Castro L, Roblero JP, Estela R.
    Transplant Proc; 2011 Feb 09; 43(6):2307-10. PubMed ID: 21839260
    [Abstract] [Full Text] [Related]

  • 39. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
    Chadban SJ, Eris JM, Kanellis J, Pilmore H, Lee PC, Lim SK, Woodcock C, Kurstjens N, Russ G, SOCRATES Study Group.
    Transpl Int; 2014 Mar 09; 27(3):302-11. PubMed ID: 24279685
    [Abstract] [Full Text] [Related]

  • 40. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 09; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.